|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for ERBB3(NM_001982.3) Search again
Product ID:
HQP054304
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
ErbB-3, FERLK, HER3, LCCS2, MDA-BF-1, VSCN1, c-erbB-3, c-erbB3, erbB3-S, p180-ErbB3, p45-sErbB3, p85-sErbB3
Gene Description:
erb-b2 receptor tyrosine kinase 3
Target Gene Accession:
NM_001982.3(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Summary
This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation.
Gene References into function
- AP-2gamma is important in the regulation of Erbb-3 expression in human mammary epithelial and lung fibroblast cells
- Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers
- Role of the N-terminus of epidermal growth factor in binding studied by phage display.
- structure reveals a contact between domains II and IV that constrains the relative orientations of ligand-binding domains
- Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of this epidermal growth factor receptor family member
- role of overexpression in lung cancer development in conjunction with erb-B-2 overexpression
- the ErbB-3 affinity of a ligand determines whether it can form only ErbB-2/ErbB-3 complexes or also ErbB-3 homodimers.
- Activation of ErbB3 pathway may contribute to the development of dedifferentiated carcinomas
- Expression of epidermal growth factor receptor, erbB2, and erbB3, but not erbB4, was detected throughout the epidermis. Labeling for erbB2 and erbB3 accentuated in upper spinous layers
- These results suggest that ErbB3 expression alone does not uniquely confer IFN-alpha growth responsiveness, but instead may amplify proliferation rates in MM cells that have acquired atypical expression of this receptor.
- ErbB2/ErbB3 dimer functions as an oncogenic unit to drive breast tumor cell proliferation.
- ERBB2 and ERBB3 expression is inhibited by quercetin, resulting in decreased autophosphorylation and cell growth
- Overexpression of ErbB3 is associated with transitional cell carcinoma of the bladder
- ErbB3 is involved in IFN-alpha-induced proliferation of myeloma cells.
- heterodimer formation with heregulin regulates erbB2 receptor
- This review summarizes evidence of defective expression of erbB3 in the prefrontal cortex of schizophrenic patients, implicating erbB3 involvement in the pathogenesis of schizophrenia.
- ErbB3 is an obligate heterodimerization partner because of its inability to homodimerize.
- before extracellular signal-regulated kinase activation and aquaporin synthesis, the membrane-bound prohormone neuregulin 1-beta is cleaved and binds to human epidermal growth factor receptor 3
- calculated binding free energies between the N-SH2 domain of PI-3 kinase and P-peptides generated by erbb3 showed excellent qualitative agreement with SPR data with a correlation coefficient of 0.91
- most of the ErbB3-ECD on the cell surface is apparently kept in an open conformation through oligomerization
- ErbB3 proteins are promising targets for therapy, and siRNAs may be useful for this purpose.
- Potential of anti-HER3 antibodies for the therapy of breast cancer and other malignancies characterized by overexpression of HER3.
- Inhibition of HER2/HER3 signaling protects against pulmonary fibrosis and improves survival.
- Transcriptional activity of eztrogen receptor beta was altered in a manner similar to ERalpha by activation of ErbB2/ErbB3.
- Cell proliferation was increased when ErbB2 and ErbB3 were both overexpressed.
- the most notable changes consisted in the overexpression of ErbB3 by Schwann cells of nerves from Charcot-Marie-tooth disease type 1A patients
- ERBB3 is the pivotal element of the Erbb pathway promoting tumorigenesis by heterodimerization with NEU or EGFR, but the NEU/EGFR dimer does not appear to play a significant role in prostate cancer
- HER2 overexpression was the best single predictive marker, but combinations of HER3, HER2 markers provided additional predictive information.
- The high frequency of ErbB3 nuclear localization in hormone-refractory tissues indicates that ErbB3 warrants further study to understand its association with prostate cancer disease progression.
- HER3 and HER4 has been related to a favourable prognosis in bladder cancer.
- Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3
- ErbB3 has six binding sites for PI3K. All three Y-E-Y motifs contain a binding site for PI3K at the first tyrosine residue. 2 motifs contain a binding site for Grb2 at the second tyrosine.
- the neuregulin/ERBB3 signaling pathway is constitutively activated in clear cell sarcoma of soft tissue
- Sox10-regulated overexpression of ErbB3 may be driving growth in pilocytic astrocytoma.
- failure to find genetic association suggests that the differential expression of ERBB3 in schizophrenia may be environmentally driven, or involve cis- or trans-acting genetic factors beyond the boundaries of the gene itself
- enhanced signaling from the HER2/neu-HER3 pathway has a role in growth of tumors treated with fulvestrant in the presence of physiologic estradiol: pertuzumab partially inhibits growth and HER2/neu with HER3 interact in vivo
- Neuregulin 1-induced protein stability cascade involving USP8 and Nrdp1 mediates the down-regulation of ErbB3
- there were no significant association between the polymorphisms or haplotypes of ERBB3 and schizophrenia; study shows that ERBB3 does not play a major role in conferring susceptibility to schizophrenia in the Japanese population
- findings show that amplification of MET causes gefitinib resistance in lung cancer by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors
- HER3 signaling pathway plays an important role in the biological behavior of certain non-small cell lung cancers.
- Increased expression of erbB3 may play an additional role in non-small-cell lung carcinomas especially in female, nonsmoker, adenocarcinoma, and with EGFR gene mutation.
- Nuclear localization of ErbB-3 may aid prostate cancer cell survival during androgen ablation and progression of prostate cancer in bone.
- p45-sErbB3 may mediate the bidirectional interactions between prostate cancer cells and bone via osteonectin
- These data suggest that the distinct topography of receptors and their docking partners modulates signaling activities.
- analysis of EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases
- Ligand-induced structural transitions in ERBB3 extracellular domains are reported.
- Lethal congenital contractural syndrome type 2 is caused by aberrant splicing of ERBB3, which leads to a predicted truncated protein.
- results demonstrate that Bmx is a critical downstream target of the constitutively active PI 3-kinase in PTEN-deficient PCa cells and further show that Bmx is recruited by the EGF receptor and ErbB3 and activated in response to their respective ligands
- ErbB-3 expression was associated with better prognosis in invasive ductal carcinomas of the breast.
- N-glycosylation controls ErbB signaling by various mechanisms.
- disruption of surface HSP90/HER-2 interaction leads to inhibition of heregulin-induced HER-2-HER-3 heterodimer formation, reduced HER-2 phosphorylation, and impaired downstream kinase signaling.
- Strong HER3 staining was found in 26.7% of both the primary tumors and the corresponding metastases.
- HER3 gene amplification showed a univariate negative impact on disease-free survival
- In human uterine leiomyomas, ERBB3 were also overexpressed.
- the alpha6beta4 integrin strongly influence Akt phosphorylation through ErbB-3 protein regulation
- Elevated EGFR, Her2, and Erbb3 phosphotyrosine is dependent on FGFR2; shRNA to Erbb3 resulted in a loss of proliferation in gastric neoplasms.
- HRG-induced activation of ErbB3 via EGFR promotes tumor growth and metastasis of melanoma cells
- Her3 showed significantly increased expression in differentiated thyroid cancer and correlated with lymph node metastasis,tumor type,and higher N stage
- The apparent correlation between higher sErbB3 levels and longer time to bone metastasis suggests that sErbB3 participates in progression in bone of prostate cancer.
- Datas show that transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.
- inhibition of HER3 may be more clinically relevant than inhibition of EGFR in HER2-amplified breast cancer and adding pertuzumab to trastuzumab may augment therapeutic benefit by blocking HER2/HER3 signaling
- Our results provide novel insights into the role of HER3 in melanoma and point out new possibilities for therapeutic intervention
- Patients with HER2 nonamplified and HER1 through HER3-negative tumors showed significantly increased relapse-free and overall survival rates when treated with epirubucin-CMF.
- Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation has a role in the synergistic action of cAMP on Schwann cell proliferation
- These data support a role for EBP1 in the development of hormone-refractory prostate cancer.
- ERBB3 receptors are apparently segregated from ERBB2 receptors in their resting state, and both ligand-activated ERBB3 and ERBB2 do not share the same microenvironment as inactive ERBB3
- HER3 and HER4 gene transcription is associated with better prognosis in high-risk early breast cancer.
- HER3 overexpression is strongly associated with tumor progression and poor prognosis of patients with gastric cancer
- The biological function and clinical implications of HRG, HER-3 and HER-4 in breast cancers negative/low expression of HER-2 remain unclear